Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. 2019;393:169–82.

Article  PubMed  Google Scholar 

Force USPST, Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, et al. Screening for cervical cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;320:674–86.

Article  Google Scholar 

Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202:1789–99.

Article  PubMed  Google Scholar 

Sonawane K, Nyitray AG, Nemutlu GS, Swartz MD, Chhatwal J, Deshmukh AA. Prevalence of human papillomavirus infection by number of vaccine doses among US women. JAMA Netw Open. 2019;2:e1918571.

Article  PubMed  PubMed Central  Google Scholar 

Wright TC Jr, Behrens CM, Ranger-Moore J, Rehm S, Sharma A, Stoler MH, et al. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: results from a sub-study nested into the ATHENA trial. Gynecol Oncol. 2017;144:51–6.

Article  PubMed  Google Scholar 

Nelson EJ, Maynard BR, Loux T, Fatla J, Gordon R, Arnold LD. The acceptability of self-sampled screening for HPV DNA: a systematic review and meta-analysis. Sex Transm Infect. 2017;93:56–61.

Article  PubMed  Google Scholar 

Polman NJ, Ebisch RMF, Heideman DAM, Melchers WJG, Bekkers RLM, Molijn AC, et al. Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial. Lancet Oncol. 2019;20:229–38.

Article  PubMed  Google Scholar 

Sancho-Garnier H, Tamalet C, Halfon P, Leandri FX, Le Retraite L, Djoufelkit K, et al. HPV self-sampling or the Pap-smear: a randomized study among cervical screening nonattenders from lower socioeconomic groups in France. Int J Cancer. 2013;133:2681–7.

PubMed  CAS  Google Scholar 

Broberg G, Gyrd-Hansen D, Miao Jonasson J, Ryd ML, Holtenman M, Milsom I, et al. Increasing participation in cervical cancer screening: offering a HPV self-test to long-term non-attendees as part of RACOMIP, a Swedish randomized controlled trial. Int J Cancer. 2014;134:2223–30.

Article  PubMed  CAS  Google Scholar 

Cadman L, Wilkes S, Mansour D, Austin J, Ashdown-Barr L, Edwards R, et al. A randomized controlled trial in non-responders from Newcastle upon Tyne invited to return a self-sample for human papillomavirus testing versus repeat invitation for cervical screening. J Med Screen. 2015;22:28–37.

Article  PubMed  Google Scholar 

Widschwendter A, Gattringer C, Ivarsson L, Fiegl H, Schneitter A, Ramoni A, et al. Analysis of aberrant DNA methylation and human papillomavirus DNA in cervicovaginal specimens to detect invasive cervical cancer and its precursors. Clin Cancer Res. 2004;10:3396–400.

Article  PubMed  CAS  Google Scholar 

Doufekas K, Hadwin R, Kandimalla R, et al. GALR1 methylation in vaginal swabs is highly accurate in identifying women with endometrial cancer. Int J Gynecol Cancer. 2013;23(6):1050–5.

Article  PubMed  Google Scholar 

Kelly H, Benavente Y, Pavon MA, De Sanjose S, Mayaud P, Lorincz AT. Performance of DNA methylation assays for detection of high-grade cervical intraepithelial neoplasia (CIN2+): a systematic review and meta-analysis. Br J Cancer. 2019;121:954–65.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Fontham ETH, Wolf AMD, Church TR, Etzioni R, Flowers CR, Herzig A, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020;70(5):321–46. https://doi.org/10.3322/caac.21628. Epub 2020 Jul 30. PMID: 32729638.

Beiersdorf J, Scheungraber C, Wunsch K, Schmitz M, Hansel A, Hoyer H, et al. Combined assessment of 3q26 amplification and promoter methylation in patients with high grade cervical lesions show age specific differences. Genes Chromosomes Cancer. 2020;59:168–77.

Article  PubMed  CAS  Google Scholar 

Leeman A, Del Pino M, Marimon L, Torne A, Ordi J, Ter Harmsel B, et al. Reliable identification of women with CIN3+ using hrHPV genotyping and methylation markers in a cytology-screened referral population. Int J Cancer. 2019;144:160–8.

Article  PubMed  CAS  Google Scholar 

Bonde J, Floore A, Ejegod D, Vink FJ, Hesselink A, van de Ven PM, et al. Methylation markers FAM19A4 and miR124-2 as triage strategy for primary HPV screen positive women; a large European multi-center study. Int J Cancer. 2021;148(2):396–405. https://doi.org/10.1002/ijc.33320. Epub 2020 Oct 21. PMID: 32997803; PMCID: PMC7756277.

De Strooper LMA, Berkhof J, Steenbergen RDM, Lissenberg-Witte BI, Snijders PJF, Meijer C, et al. Cervical cancer risk in HPV-positive women after a negative FAM19A4/mir124-2 methylation test: a post hoc analysis in the POBASCAM trial with 14 year follow-up. Int J Cancer. 2018;143:1541–8.

Article  PubMed  PubMed Central  Google Scholar 

Lei J, Ploner A, Elfstrom KM, Wang J, Roth A, Fang F, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020;383:1340–8.

Article  PubMed  CAS  Google Scholar 

Perskvist N, Norman I, Eklund C, Litton JE, Dillner J. The Swedish cervical cytology biobank: sample handling and storage process. Biopreserv Biobank. 2013;11:19–24.

Article  PubMed  Google Scholar 

Ludvigsson JF, Almqvist C, Bonamy AK, Ljung R, Michaelsson K, Neovius M, et al. Registers of the Swedish total population and their use in medical research. Eur J Epidemiol. 2016;31:125–36.

Article  PubMed  Google Scholar 

Elfstrom KM, Eklund C, Lamin H, Ohman D, Hortlund M, Elfgren K, et al. Organized primary human papillomavirus-based cervical screening: a randomized healthcare policy trial. PLoS Med. 2021;18:e1003748.

Article  PubMed  PubMed Central  Google Scholar 

Hortlund M, Sundstrom K, Lamin H, Hjerpe A, Dillner J. Laboratory audit as part of the quality assessment of a primary HPV-screening program. J Clin Virol. 2016;75:33–6.

Article  PubMed  Google Scholar 

Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen KD, et al. Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics. 2014;30:1363–9.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hastie T, Tibshirani R, Narasimhan B, Chu G. impute: impute: Imputation for microarray data. R package version 1.70.0. 2022. http://www.bioconductor.org/packages/release/bioc/html/impute.html.

Zhou W, Laird PW, Shen H. Comprehensive characterization, annotation and innovative use of Infinium DNA methylation BeadChip probes. Nucleic Acids Res. 2017;45:e22.

PubMed  Google Scholar 

Teschendorff AE, Marabita F, Lechner M, Bartlett T, Tegner J, Gomez-Cabrero D, et al. A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data. Bioinformatics. 2013;29:189–96.

Article  PubMed  CAS  Google Scholar 

Zheng SC, Webster AP, Dong D, Feber A, Graham DG, Sullivan R, et al. A novel cell-type deconvolution algorithm reveals substantial contamination by immune cells in saliva, buccal and cervix. Epigenomics. 2018;10:925–40.

Article  PubMed  CAS  Google Scholar 

Barrett JE, Herzog C, Jones A, Leavy OC, Evans I, Knapp S, et al. The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples. Nat Commun. 2022;13:449.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33:1–22.

Article  PubMed  PubMed Central  Google Scholar 

Teschendorff AE, Menon U, Gentry-Maharaj A, Ramus SJ, Gayther SA, Apostolidou S, et al. An epigenetic signature in peripheral blood predicts active ovarian cancer. PLoS One. 2009;4:e8274.

Article  PubMed  PubMed Central  Google Scholar 

Pidsley R, Zotenko E, Peters TJ, Lawrence MG, Risbridger GP, Molloy P, et al. Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA methylation profiling. Genome Biol. 2016;17:208.

Article  PubMed  PubMed Central  Google Scholar 

Tainio K, Athanasiou A, Tikkinen KAO, Aaltonen R, Cardenas J, Hernandes G-LS, et al. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis. BMJ. 2018;360:k499.

Article  PubMed  PubMed Central  Google Scholar 

Verhoef VM, Bosgraaf RP, van Kemenade FJ, Rozendaal L, Heideman DA, Hesselink AT, et al. Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial. Lancet Oncol. 2014;15:315–22.

Article  PubMed  CAS  Google Scholar 

Widschwendter M, Jones A, Evans I, Reisel D, Dillner J, Sundstrom K, et al. Epigenome-based cancer risk prediction: rationale, opportunities and challenges. Nat Rev Clin Oncol. 2018;15:292–309.

Article  PubMed  Google Scholar 

Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008;337:a1754.

Article  PubMed  PubMed Central  Google Scholar 

Barrett JE, Jones A, Evans I, Reisel D, Herzog C, Chindera K, et al. The DNA methylome of cervical cells can predict the presence of ovarian cancer. Nat Commun. 2022;13:448.

Article  PubMed  PubMed Central  CAS  Google Scholar